Microbial life in 25-m-deep boreholes in ancient permafrost illuminated by metagenomics.

Autor: Wu X; Center for Environmental Biotechnology, University of Tennessee, 1416 Circle Drive, Knoxville, TN, 37996-1605, USA., Almatari AL; Center for Environmental Biotechnology, University of Tennessee, 1416 Circle Drive, Knoxville, TN, 37996-1605, USA., Cyr WA; Center for Environmental Biotechnology, University of Tennessee, 1416 Circle Drive, Knoxville, TN, 37996-1605, USA., Williams DE; Center for Environmental Biotechnology, University of Tennessee, 1416 Circle Drive, Knoxville, TN, 37996-1605, USA., Pfiffner SM; Center for Environmental Biotechnology, University of Tennessee, 1416 Circle Drive, Knoxville, TN, 37996-1605, USA., Rivkina EM; Soil Cryology Laboratory, Institute of Physicochemical and Biological Problems in Soil Science, Russian Academy of Sciences, Pushchino, Russia, 142290., Lloyd KG; Department of Microbiology, University of Tennessee, Knoxville, TN, 37996, USA., Vishnivetskaya TA; Center for Environmental Biotechnology, University of Tennessee, 1416 Circle Drive, Knoxville, TN, 37996-1605, USA. tvishniv@utk.edu.; Soil Cryology Laboratory, Institute of Physicochemical and Biological Problems in Soil Science, Russian Academy of Sciences, Pushchino, Russia, 142290. tvishniv@utk.edu.; Department of Microbiology, University of Tennessee, Knoxville, TN, 37996, USA. tvishniv@utk.edu.

Publikováno v: Environmental microbiome [Environ Microbiome] 2023 Apr 13; Vol. 18 (1), pp. 33. Date of Electronic Publication: 2023 Apr 13.

Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.

Autor: Ganesh S; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts. sganesh@dicerna.com., Koser ML; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Cyr WA; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Chopda GR; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Tao J; University of Pittsburgh Medical Center, Pittsburgh, Pittsburgh., Shui X; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Ying B; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Chen D; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Pandya P; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Chipumuro E; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Siddiquee Z; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Craig K; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Lai C; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Dudek H; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Monga SP; University of Pittsburgh Medical Center, Pittsburgh, Pittsburgh., Wang W; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Brown BD; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts., Abrams MT; Dicerna Pharmaceuticals, Inc., Cambridge, Massachusetts.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2016 Sep; Vol. 15 (9), pp. 2143-54. Date of Electronic Publication: 2016 Jul 07.

Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo.

Autor: Dudek H; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Wong DH; 1] Dicerna Pharmaceuticals, Watertown, Massachusetts, USA [2] Current addresses: Shire Human Genetic Therapies, Lexington, Massachusetts, USA (S.K.B.); Acceleron Pharma, Cambridge, Massachusetts, USA (M.L.); Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA (Y.L.); Medivation, San Francisco, California, USA (D.H.W.)., Arvan R; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Shah A; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Wortham K; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Ying B; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Diwanji R; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Zhou W; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Holmes B; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Yang H; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Cyr WA; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Zhou Y; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Shah A; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Farkiwala R; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA., Lee M; 1] Dicerna Pharmaceuticals, Watertown, Massachusetts, USA [2] Current addresses: Shire Human Genetic Therapies, Lexington, Massachusetts, USA (S.K.B.); Acceleron Pharma, Cambridge, Massachusetts, USA (M.L.); Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA (Y.L.); Medivation, San Francisco, California, USA (D.H.W.)., Li Y; 1] Dicerna Pharmaceuticals, Watertown, Massachusetts, USA [2] Current addresses: Shire Human Genetic Therapies, Lexington, Massachusetts, USA (S.K.B.); Acceleron Pharma, Cambridge, Massachusetts, USA (M.L.); Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA (Y.L.); Medivation, San Francisco, California, USA (D.H.W.)., Rettig GR; Integrated DNA Technologies, Coralville, Iowa, USA., Collingwood MA; Integrated DNA Technologies, Coralville, Iowa, USA., Basu SK; 1] Dicerna Pharmaceuticals, Watertown, Massachusetts, USA [2] Current addresses: Shire Human Genetic Therapies, Lexington, Massachusetts, USA (S.K.B.); Acceleron Pharma, Cambridge, Massachusetts, USA (M.L.); Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA (Y.L.); Medivation, San Francisco, California, USA (D.H.W.)., Behlke MA; Integrated DNA Technologies, Coralville, Iowa, USA., Brown BD; Dicerna Pharmaceuticals, Watertown, Massachusetts, USA.

Publikováno v: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2014 Jan; Vol. 22 (1), pp. 92-101. Date of Electronic Publication: 2013 Oct 03.